Department of Endocrinology and Metabolic Diseases, Universitatsmedizin der Johannes Gutenberg, Mainz, Germany.
Clinical Research Services, Manhheim, Germany.
Diabetes Metab Res Rev. 2021 Sep;37(6):e3418. doi: 10.1002/dmrr.3418. Epub 2020 Dec 1.
Initiating insulin therapy with a basal insulin analogue has become a standard of care in the treatment of type 2 diabetes mellitus (T2DM). Despite increasing choices in pharmacological approaches, intensified glucose monitoring and improvements in quality of care, many patients do not achieve the desired level of glycaemic control. Although insulin therapy, when optimized, can help patients reach their glycaemic goals, there are barriers to treatment initiation on both the side of the patient and provider. Providers experience barriers based on their perceptions of patients' capabilities and concerns. They may lack the confidence to solve the practical problems of insulin therapy and avoid decisions they perceive as risky for their patients. In this study, we review recommendations for basal insulin initiation, focussing on glycaemic targets, titration, monitoring, and combination therapy with non-insulin anti-hyperglycaemic medications. We provide practical advice on how to address some of the key problems encountered in everyday clinical practice and give recommendations where there are gaps in knowledge or guidelines. We also discuss common challenges faced by people with T2DM, such as weight gain and hypoglycaemia, and how providers can address and overcome them.
在治疗 2 型糖尿病(T2DM)中,起始使用基础胰岛素类似物已成为一种标准治疗方法。尽管在药物治疗方法上有了更多的选择、强化了血糖监测以及改善了护理质量,但许多患者仍无法达到理想的血糖控制水平。尽管胰岛素治疗在优化后可以帮助患者达到血糖目标,但在患者和医务人员两方面都存在治疗起始的障碍。医务人员会因为他们对患者能力和担忧的看法而遇到障碍。他们可能缺乏解决胰岛素治疗实际问题的信心,避免他们认为对患者有风险的决策。在这项研究中,我们回顾了基础胰岛素起始的建议,重点关注血糖目标、滴定、监测以及与非胰岛素类降糖药物的联合治疗。我们就如何解决日常临床实践中遇到的一些关键问题提供了实用建议,并在知识或指南存在空白的地方提出了建议。我们还讨论了 T2DM 患者面临的常见挑战,如体重增加和低血糖,以及医务人员如何应对和克服这些挑战。